Acoustic rhinometry: an explanation of some common artefacts associated with nasal decongestion.
The nasal cavities of 51 healthy volunteers were examined using acoustic rhinometry before and after nasal decongestant. Several specific dimensions were studied, which included the minimum cross-sectional area, and three volumes corresponding to the anterior, middle and posterior regions of the nasal airway. An average acoustic rhinometry trace was constructed for the whole group of subjects, before and after decongestion, from data extracted from the raw data files written to the computer hard disk for each subject. A 27.5% (P < 0.0001) increase in the minimum cross-sectional area was observed, with no shift in its position. The greatest increase in nasal dimensions was seen in the anterior and middle parts of the nose, however, significant changes were also seen in the posterior nasal cavity and post nasal space. There are a number of possible sources of artefact. First, confusion of the first and second minima may produce apparent movement of the minimum cross-sectional area following nasal decongestion. Second, a postulated change in the acoustic path length may lead to apparent changes in volume in certain regions of the nose. Third, a variable and uncontrollable degree of sound energy loss will occur into the opposite nasal cavity beyond the posterior border of the septum. An apparent increase in the dimensions of this region will be seen as the opposite cavity decongests. We feel that all users of the acoustic rhinometer need to be aware of these potential sources of artefact, and attention needs to be focused on an agreed definition of the components of the acoustic rhinometry trace.
Tomkinson
A
A
The Common Cold Centre, School of Molecular and Medical Biosciences, University of Wales College of Cardiff, UK.
Eccles
R
R
D000162:Acoustics; D000281:Administration, Intranasal; D000328:Adult; D016477:Artifacts; D005260:Female; D006801:Humans; D008297:Male; D009296:Nasal Cavity / Q000033:anatomy & histology* / Q000187:drug effects; D014663:Nasal Decongestants / Q000008:administration & dosage; D015508:Nasal Obstruction / Q000175:diagnosis; D010109:Oxymetazoline / Q000008:administration & dosage; D012016:Reference Values; D009626:Terminology as Topic
D014663:Nasal Decongestants; D010109:Oxymetazoline